Hexarelin: Side Effects & Safety

Hexarelin (examorelin) is one of the earliest synthetic GH secretagogues, developed by Pharmacia Italy in the early 1990s and most extensively characterized in published research by the Ghigo and Locatelli groups in Italy.^[1] The clinical safety picture is well-documented for acute and short-term use; chronic long-term safety data is more limited.

The defining safety distinction from other GHRPs (ipamorelin, GHRP-2, GHRP-6) is hexarelin's lack of selectivity — it produces meaningful cortisol and prolactin elevation alongside GH release, plus it desensitizes the GHSR-1a receptor with chronic dosing. These properties define both its practical clinical use and its safety considerations.

Hexarelin is not FDA-approved for any indication and is not on the July 2026 FDA Pharmacy Compounding Advisory Committee 503A bulks list agenda. It is sold for "research" purposes only.

Effect	Frequency / Mechanism	Notes
Cortisol elevation	Common, dose-dependent	ACTH-mediated; higher than ipamorelin/GHRP-2 and lower than GHRP-6
Prolactin elevation	Common, dose-dependent	Can affect reproductive function, libido, mood with chronic exposure
Appetite stimulation	Moderate	Ghrelin-mediated; less than GHRP-6, more than ipamorelin
GHSR-1a desensitization	Predictable with chronic dosing	GH response diminishes substantially by week 4–8; unique among GHRPs
Injection-site reactions	Common (mild)	Redness, mild soreness; rotate sites
Transient flushing / warmth	Common (post-injection)	Lasting 5–10 minutes; vasodilatory
Mild water retention	Common	GH-mediated; usually subtle
Headache	Occasional	Usually transient, first few doses
Tingling / paresthesia in extremities	Uncommon	Possible carpal-tunnel-pattern with sustained GH elevation
Mild hypotension	Uncommon	Transient post-injection, vasodilatory
Joint pain (chronic high-dose use)	Rare	Possible GH/IGF-1 class effect

No serious adverse events have been reported in the published Italian clinical trials at standard doses. Long-term continuous-dose data in healthy adults beyond ~16 weeks is limited.

Hexarelin's lack of selectivity is the most important practical safety difference from ipamorelin and GHRP-2. The mechanism is that hexarelin activates additional receptors (ACTH-axis stimulation, prolactin release) beyond the GHSR-1a that mediates GH release.

Cortisol

Hexarelin produces a dose-dependent rise in serum cortisol of approximately 30–50% above baseline at standard research doses. Effects of sustained mild cortisol elevation include:

• Visceral fat accumulation (central / abdominal weight gain)
• Muscle protein catabolism (opposing the anabolic GH effect)
• Reduced immune function
• Sleep disruption (especially if dosed late in the day)
• Mood effects (anxiety, irritability)

Prolactin

Prolactin elevation can produce:

• Reduced libido and sexual function
• Galactorrhea (milk production) — rare
• Menstrual irregularities in women
• Mood changes, dysphoria

These effects are dose-dependent and largely reversible on discontinuation. They are the primary reason ipamorelin is preferred for long-term GH optimization protocols.

Continuous daily hexarelin dosing produces predictable GHSR-1a receptor desensitization: GH response is substantially blunted by week 4 and largely absent by week 8.^[2] While this limits long-term effectiveness, it also has a safety upside — patients cannot drift into supraphysiological IGF-1 elevation on chronic hexarelin the way they can on continuous CJC-1295-DAC.

Practical implications:

• Cycle 4 weeks on / 2 weeks off allows receptor recovery and maintains response over time.
• The cardiac CD36-mediated effects operate through a separate receptor and may persist even when GH response has declined.
• "Stacking" hexarelin with itself (higher doses) does not overcome desensitization — only time off does.

• Hyperprolactinemia or prolactin-secreting tumors: contraindicated; hexarelin further elevates prolactin.
• Cushing's syndrome or conditions worsened by cortisol (severe osteoporosis, poorly controlled diabetes, severe depression): use caution or avoid.
• Active or recent malignancy: GH and IGF-1 are mitogenic. Absolute contraindication.
• Active diabetic retinopathy: GH can worsen retinopathy.
• Uncontrolled diabetes: GH antagonizes insulin; can worsen glycemic control.
• Pregnancy and breastfeeding: contraindicated.
• Acromegaly or pituitary tumors: contraindicated.
• Severe cardiac arrhythmia or recent ischemic event: caution; despite cardioprotective effects in research, acute cardiovascular events warrant medical supervision.
• Carpal tunnel syndrome: relative contraindication (GH-mediated fluid retention).
• Known hypersensitivity to hexarelin or formulation excipients.

Drug interactions

• Insulin / sulfonylureas: GH antagonizes insulin. Monitor glucose more closely.
• Glucocorticoids (prednisone, dexamethasone): additive cortisol burden. Avoid combining.
• Dopamine agonists (cabergoline, bromocriptine): may oppose hexarelin's prolactin elevation; potentially used to mitigate but not well-studied.
• Other GH secretagogues (ipamorelin, GHRP-2, GHRP-6): competitive at GHSR-1a; no benefit to combining. May combine with GHRH analogs (sermorelin, CJC-1295 Mod GRF 1-29) for additive GH release.
• Levothyroxine: GH can affect T4-to-T3 conversion. Monitor thyroid function during chronic use.

• Mild injection-site reactions: rotate sites; resolve within 24–48 hours.
• Persistent flushing or hypotension: reduce dose; lie down after injection.
• Reduced libido, mood changes, galactorrhea: stop and check prolactin level. May resolve with discontinuation.
• Visceral weight gain, sleep disruption, mood lability: consider cortisol elevation. Reduce dose, move all doses to before 14:00, or switch to ipamorelin.
• Tingling in hands, swelling, joint pain: GH-pattern; reduce dose or discontinue.
• Loss of GH effect after week 4–8: expected desensitization — cycle off for 2 weeks. Switch to ipamorelin during the break.
• Vision changes (diabetic patients): ophthalmology evaluation for retinopathy.
• Elevated fasting glucose: reduce dose; discontinue if persistent.
• Allergic reaction: discontinue immediately and seek emergency care.

See the hexarelin complete guide, dosage protocols, benefits and research, and the hexarelin vs ipamorelin comparison.